Yes but certainly not fast tracked as so many posters suggested and duration testing means no read out until 2022. So don't take up tea leaf reading as Paul didn't waiver from the Bene issue in his virtual conference call!
More onerous FDA requirements for phase 3, that should lead to compelling end product and market penetration .
Ann: Paradigm receives clarity on US regulatory pathway, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
42.0¢ |
Change
0.010(2.44%) |
Mkt cap ! $166.9M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 42.0¢ | 40.0¢ | $168.2K | 411.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3500 | 41.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 50665 | 2 |
View Market Depth
| Last trade - 16.11pm 18/07/2025 (20 minute delay) ? |
| PAR (ASX) Chart |